Navigation

betaxolol (Kerlone)

 

Classes: Beta-Blockers, Beta-1 Selective

Dosing and uses of Betoptic S, Kerlone (betaxolol)

 

Adult dosage forms and strengths

tablet

  • 10mg
  • 20mg

 

Hypertension

5-20 mg PO qDay

 

Renal Impairment

Severe impairment: 5 mg PO qDay; may increase every 2 weeks to maximum 20 mg/day

 

Other Information

Less effective than thiazide diuretics in black and geriatric patients

Shown to decrease mortality in hypertension and post-myocardial infarction

 

Pediatric dosage forms and strengths

 

Hypertension

Safety and efficacy not established

 

Geriatric dosage forms and strengths

Hypertension: 5 mg PO qDay

Consideration should be given to reducing the starting dose to 5 mg in elderly patients

Elderly are especially prone to beta-blocker–induced bradycardia, which appears to be dose related and sometimes responds to reductions in dose

 

Betoptic S, Kerlone (betaxolol) adverse (side) effects

2-10%

Fatigue (2-10%)

Bradycardia (6-8%)

Chest pain (2-7%)

Dyspepsia (2-5%)

Lethargy (3%)

Cold extremeties (2%)

Diarrhea (2%)

Dyspnea (2%)

Edema (2%)

Palpitation (2%)

Pharyngitis (2%)

 

<2% (selected)

Angina

Arrhythmia

Flushing

Depression

Fever

Hallucinations

Malaise

Neuropathy

Rash

Diabetes

Hyperglycemia

Anemia

Hypercholesterolemia

Hyperlipidemia

Leukocytosis

cataracts

Constipation

Dysphagia

Libido decreased

Proteinuria

Bronchospams

Cough

 

Frequency not defined

Decreased exercise tolerance, Raynaud's phenomenon

May increase triglyceride levels and insulin resistance, and decrease HDL levels

 

Warnings

Contraindications

Sinus bradycardia, 2°/3° heart block, cardiogenic shock, overt cardiac failure, hypersensitivity, sick sinus syndrome without permanent pacemaker

 

Cautions

Bronchospastic disease, cerebrovascular insufficiency, CHF, cardiomegaly, DM, hyperthyroidism/thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease (potential risk of reduced placental perfusion, fetal bradycardia, hypoglycemia), use in pheochromocytoma, IDDm

Surgery/Anesthesia: Chronically administered beta-blockers should not be routinely withdrawn prior to major surgery; however, impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures

 

Pregnancy and lactation

Pregnancy category: C

Lactation: excreted in milk; use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Betoptic S, Kerlone (betaxolol)

Mechanism of action

Beta adrenergic receptor blocker; cardioselective for Beta-1 receptor at low doses

 

Pharmacokinetics

Half-Life: 14-22 hr

Bioavailability: 89%

Protein Bound: 50%

Excretion: Urine

Onset of action: 1-1.5hr

Peak Plasma

  • Time: 3 hr
  • Concentration: 21.6 ng/mL